VolitionRx Limited — FY 2016 Form 10-K
Business context and reporting period. This annual report covers the fiscal year ended December 31, 2016, with comparisons to 2015. VolitionRx is a development-stage life sciences company developing blood-based cancer diagnostics using its Nucleosomics platform. In December 2016, its Nu.Q Colorectal Cancer Screening Triage Test received a CE Mark, moving the company toward commercialization. The test is intended to be used with a positive FIT result to help reduce unnecessary colonoscopies; it is not described as a standalone frontline screening test.
Financial results and position
| Metric | 2016 | 2015 |
|---|---|---|
| Revenue | $0 | $0 |
| Operating expenses | $12.27 million | $10.01 million |
| Research and development expense | $6.84 million | $6.10 million |
| Net loss | $11.91 million | $9.53 million |
| Basic and diluted loss per share | $0.52 | $0.54 |
| Net cash used in operations | $9.06 million | $8.55 million |
- Cash and liquidity: Cash and cash equivalents were $21.68 million at year-end, versus $5.92 million in 2015. Working capital surplus was $19.98 million; current liabilities were $2.03 million.
- Cash flows and funding: Financing activities provided $25.38 million, primarily from 2016 public offerings. Net cash increased by $15.76 million during the year. Operating cash use rose by about $0.51 million year over year.
- Debt and leases: Balance-sheet long-term debt was $432,027, plus a $30,655 current portion. Capital lease liabilities totaled about $1.01 million, including $119,016 current. Grant repayments outstanding were about $239,000.
- Equity and accumulated losses: Stockholders’ equity was $21.18 million and accumulated deficit was $40.94 million. Shares outstanding increased from 18.76 million at year-end 2015 to 26.13 million at year-end 2016, mainly reflecting equity financing.
- Margins: No meaningful operating margin is available because the company reported no revenue.
Material changes versus 2015
- Operating expenses increased 22.6%; net loss widened 24.9%. Higher R&D, professional fees, and salaries and administration drove most of the increase.
- R&D expense increased 12.1%, including higher costs for Hvidovre Hospital studies and other research contracts.
- Net other income fell to $361,325 from $470,873. The 2015 amount included a $339,744 derivative remeasurement gain; 2016 grant income was $361,325.
- Cash increased substantially following two public offerings in 2016, but the company issued 7.31 million shares for cash during the year, diluting existing holders.
Outlook, risks, and unusual items
- Management said it did not anticipate significant revenue in 2017. It planned European and other market rollout activities after CE Marking, including pathway-design studies where appropriate.
- The company expected to pursue U.S. regulatory pathways: a 510(k) submission for a symptomatic adjunct use, with an estimated cost of $1.5–$2 million and anticipated completion in 2018; and a PMA program for CRC screening, expected to start in 2017 and complete in 2019. Management estimated PMA costs at about $5 million but noted costs could reach $50 million depending on requirements and other factors.
- Management stated that current cash was expected to fund operations for at least the next 12 months, while also warning that additional financing may be needed to execute its full plan. The independent auditor reported substantial doubt about the company’s ability to continue as a going concern, given recurring losses, negative operating cash flows, and no revenue.
- Key risks include clinical results not translating to larger studies, regulatory delays or failure, limited commercialization experience, reimbursement and market-acceptance uncertainty, competition, dependence on third-party manufacturing and distribution, and possible future financing and dilution.
- Disclosure controls and internal control over financial reporting were assessed as ineffective at year-end. Identified material weaknesses were inadequate segregation of duties in Finance and insufficient oversight in IT and Human Resources. Management said remediation was underway; the auditor did not attest to internal controls.
- Clinical evidence cited for the triage test included a separate validation set reporting a 28.6% potential reduction in colonoscopies and 91.2% sensitivity. The filing also cites earlier training-set results; these are study findings, not evidence of commercial adoption or realized revenue.
- The company acquired a Belgian R&D facility in 2016 and expected to occupy it in March 2017. It also had research commitments, lease obligations, and a Walloon Region grant repayment and potential royalty obligation.
Important facts for investors to verify
- Whether the CE-marked triage test launched as planned, generated sales, and achieved clinical and commercial adoption.
- Updated cash runway, operating cash burn, financing needs, and the effect of further share issuance or equity awards.
- Progress, cost, and timing of FDA submissions and required U.S. clinical studies, alongside any changes in European IVD requirements.
- Whether larger prospective studies reproduce the reported sensitivity and colonoscopy-reduction results in intended-use populations.
- Whether the company remediated its material weaknesses and whether future filings report effective controls.
- Current debt, capital lease and grant obligations, and any changes to research commitments or related-party arrangements.